The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
The registrational Spearhead-1 trial of afami-cel backs up the efficacy seen in phase 1, without some of the related toxicities.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?